Interleukin-5 Antagonist [EPC]

688 reported adverse events

Drugs of this class: MEPOLIZUMAB RESLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-5 Antagonist [EPC] class:

# Side effect Count
0 ASTHMA 12947
1 DYSPNOEA 10802
2 WHEEZING 7232
3 PRODUCT DOSE OMISSION ISSUE 6882
4 COUGH 5183
5 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 5093
6 DRUG INEFFECTIVE 4798
7 PNEUMONIA 4750
8 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 4281
9 FATIGUE 3188
See all common reactions for Interleukin-5 Antagonist [EPC]

Drugs of the Interleukin-5 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS 692 0.3390
1 FACET JOINT SYNDROME 773 0.2372
2 OBSTRUCTIVE AIRWAYS DISORDER 2205 0.1980
3 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 3148 0.1852
4 PERIPHERAL VENOUS DISEASE 733 0.1793
5 FULL BLOOD COUNT ABNORMAL 1873 0.1769
6 NASAL POLYPS 852 0.1729
7 ASTHMATIC CRISIS 618 0.1690
8 ONYCHOMADESIS 672 0.1600
9 BLEPHAROSPASM 813 0.1290
See all enriched reactions for Interleukin-5 Antagonist [EPC]